Print

Featured Event...

SEED Final Competition and Award Ceremony
April 23, 2010 | Shanghai, China
Register Free Now!
The finalists will present to a judges panel made up of venture capitalists, scientists, industry executives and others. There will also be industry experts speaking on the industry and entrepreneurships. The event will end with the prize ceremony followed by a reception. Attendees will include the finalists, other entrants, government representatives, industry executives, venture capitalists and investors, delegates from the press and interested parties from life science companies and universities.

>> See  www.SEED2010.com for more information on the SEED events

ChinaBio® Today - Focused solely on China biotech...

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotechnology companies and industry events, as well as global issues affecting the China life science market.

Email subscriptions are free. Just click here to register for free daily summaries of key events in China biotech. Paid subscriptions provide full access to all articles and analysis, including the over 2000 articles we've published on the biotech industry over the last four years. There is also an option to contact our analysts to answer your questions. Click here to learn more about our subscription plans.

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

  China Sky One Predicts Improved 2010; Changes Focus (in: News & Analysis)
Mar 18, 2010
China Sky One Medical (中国天字一号医药公司) expects 2010 revenues to grow by 20% to $156 million. Net income, however, will increase by a more modest 13% to $39 million, as the company ups its R&D to 15% of revenue. At the same time, the company said it will shift its corporate focus to cardiovascular medicine and antibiotic drugs. More details...

Stock Symbol: (NSDQ: CSKI)
  China Sky One’s Cancer Drug Granted “Breakthrough” Status (in: News & Analysis)
Mar 18, 2010
China Sky One Medical (中国天字一号医药公司) announced its development-stage innovative cancer drug, Antroquinonol (Hocena) capsules, has been recognized as a Breakthrough Drug by China’s Ministry of Science and Technology (MoST). The designation qualifies Antroquinonol for accelerated approvals as well as financial and technical support of its development. More details...

Stock Symbol: (NSDQ: CSKI)
  IMS Health: China Leads Emerging Pharma Markets (in: Industry Insights)
Mar 17, 2010
IMS Health has upped its count of “pharmerging” countries to 17 high-growth pharmaceutical markets. Previously, only seven markets qualified. According to IMS Health, these 17 countries represent $90 billion of increased pharmaceutical spending during 2009-13, collectively offering 48% of the growth in the market in 2013. China is the most significant opportunity of the 17, a market that is “in a league of its own,” in the words of the healthcare consultancy company. More details...

Stock Symbol: (NYSE: IMS)
  Vycor Medical to Register Brain Surgery Device in China (in: News & Analysis)
Mar 17, 2010
Vycor Medical, Inc. will seek SFDA approval for its VBAS (ViewSite™ Brain Access System), an innovative retraction system for use during brain surgery. Once the medical device is approved, Vycor will co-market the product in China with its partner, Devon Medical, Inc, which is also helping with the registration process. More details...

Stock Symbol: (OTCBB: VYCO)
  MicuRx Files IND in China for New Antibiotic (in: News & Analysis)
Mar 16, 2010
MicuRx Pharmaceuticals filed an Investigational New Drug (IND) application with the SFDA for MRX-I, its most-advanced antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets drug resistant infections. MicuRx is headquarterd in the San Francisco area, but it has a 10,000 square foot laboratory in Shanghai’s Zhangjiang High-Tech Park. More details...
  Novartis’ China Revenues Climb 36% in 2009 (in: News & Analysis)
Mar 16, 2010
Novartis AG, the Swiss multinational pharma, said revenues in China grew 36% last year, far better than the company’s overall 11% rise in sales. In 2009, Novartis China was helped by supplying 100 million doses of the company’s A(H1N1) pandemic vaccine to China. Novartis China markets pharmaceuticals, vaccines, and diagnostics. More details...

Stock Symbol: (NYSE: NVS)
  Lee’s Pharma to Distribute Recordati Hypertension Drug (in: News & Analysis)
Mar 16, 2010
Lee's Pharmaceutical Holdings Limited, which is headquartered in Hong Kong, signed an exclusive license for China distribution of a Recordati S.p.A. antihypertensive drug, Zanidip® (lercanidipine). Zanidip is a calcium channel blocker (CCB). Terms of the agreement were not disclosed. More details...

Stock Symbols: (GEM: 8221) (MI: RECI)
  FDA Issues Warning to China API Maker (in: News & Analysis)
Mar 15, 2010
The FDA has told XiAn Libang Pharmaceuticals to improve its quality control procedures, if it wants to continue importing products to the US. The US agency told the company to hire an outside auditor to develop a Corrective Action Plan and respond to the warning letter within 15 days. According to the FDA, XiAn Libang did not conduct a thorough investigation after quality control problems were discovered last summer. More details...
  The Week in Review: AutekBio Raises $100 Million for Biologic CMO (in: Week in Review)
Mar 13, 2010
AutekBio raised $100 million to build Asia’s largest biologic CMO facility in Beijing; Porton Fine Chemicals announced a $10 million funding to expand its CMO capacity; TCT Medical Technology, an OB/GYN company, booked $10 million in new capital from two Fidelity funds; EA Inc., which makes invisible dental braces, raised $6.6 million Series A from OrbiMed; Lotus Pharma (路坦制药有限公司) began building a combined office, R&D, production, and storage facility; Dr. Xiaochuan Wang, who founded Sundia MediTech (桑迪亚医药技术（上海）有限公司), was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum; and WuXi PharmaTech (药明康德) reported 2009 net revenues of $270 million, an increase of 7%, and net income of $53 million. More details…

Stock Symbols: (OTCBB: LTUS) (NYSE: WX)
  Chongqing Porton Secures $10 Million for Production Facility (in: Deals & Financings)
Mar 12, 2010
Chongqing Porton Fine Chemicals Co., a CMO, raised $10 million from the Chongqing DT Fund. The Chongqing DT Fund is a joint effort run by DT Capital of Shanghai and funded by the Chongqing Venture Capital Guidance Fund. Porton will use the money to build a state-of-the-art intermediate and API manufacturing facility in Changshou Chemical Park in Chongqing. More details...
 
more articles >>